Table of Contents
| << Previous Issue | Apr 2013 (Vol: 2013, Issue: 4) | Next Issue >> |
- Section: Licensing
-
AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis
-
NPS Pharmaceuticals Regains Global Rights to Two Orphan Drugs from Takeda
-
Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme
-
Dainippon Sumitomo Licenses Japanese Rights to Two Redox-Directed Drugs from Edison Pharmaceuticals
- Section: Mergers & Acquisitions
-
Ajinomoto Expands Biologics Development and Manufacturing Capabilities with Althea Technologies Purchase
-
Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid
-
Shire Adds Phase III Ophthalmology Asset to Pipeline with SARcode Bioscience Purchase
- Section: Research & Development
-
Celgene Endorses Presage Biosciences’ Cancer Drug Analysis Platform with Strategic Collaboration
-
Presidio and Boehringer Ingelheim Partner to Test All-Oral Combination for HCV Genotype-1a
-
AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology
-
Celgene Partners with Bluebird Bio to Advance CAR T-Cell Cancer Therapies
-
Astellas Adds to Antibody-Drug Conjugate Capabilities with Ambrx Collaboration
-
Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator
-
Isis Advances Antisense Drug for Huntington’s Disease in Collaboration with Roche
-
Santaris Pharma Gains Another Collaborator in BMS
-
Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration
-
AstraZeneca Highlights R&D Growth Strategy via Collaborations with BIND Therapeutics and Horizon Discovery
RSS